Cibinqo, also known as abrocitinib, is a JAK1 inhibitor used to treat moderate-to-severe atopic dermatitis. Sales figures for Cibinqo can provide insight into its market performance and adoption rate among patients and healthcare providers.
How are Cibinqo's sales performing?
Cibinqo's sales have shown growth since its launch. In the first quarter of 2023, Pfizer reported approximately $44 million in net sales for Cibinqo [1]. This represented an increase from previous quarters, indicating a positive trend in its commercial uptake. Pfizer noted that the growth was driven by new patient starts and market share gains in key regions [1].
When did Cibinqo receive approval?
Abrocitinib, the active ingredient in Cibinqo, received its first approval in Japan in March 2021 for the treatment of atopic dermatitis [2]. Subsequent approvals followed in other major markets, including the United States and the European Union in early 2022 [3][4]. These approvals marked the initial periods for its commercialization and sales generation.
What is the mechanism of action for Cibinqo?
Cibinqo is a selective Janus kinase 1 (JAK1) inhibitor [5]. By inhibiting JAK1, abrocitinib modulates the signaling pathways of several cytokines that play a critical role in inflammation and immune responses, such as interleukins (IL-4, IL-13, IL-31) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [5]. This targeted inhibition helps to reduce the itching and inflammation associated with atopic dermatitis.
How does Cibinqo compare to other atopic dermatitis treatments?
Cibinqo competes in a growing market for atopic dermatitis treatments, which includes other JAK inhibitors, biologics, and topical therapies. For example, other JAK inhibitors like Upadacitinib (Rinvoq) and Baricitinib (Olumiant) are also approved for atopic dermatitis and have established market presence. Biologics such as Dupilumab (Dupixent) are also significant competitors. Cibinqo's efficacy and safety profile, particularly its selectivity for JAK1, are key differentiating factors discussed in clinical trials and real-world evidence.
What are the potential risks associated with Cibinqo?
Like other JAK inhibitors, Cibinqo carries a boxed warning regarding serious infections, increased mortality in patients 50 years and older with certain cardiovascular risk factors, malignancy, major adverse cardiovascular events (MACE), and thrombosis [5]. These risks are a significant consideration for healthcare providers and patients when deciding on treatment.
What is the patent status of Cibinqo?
The patent landscape for abrocitinib is crucial for understanding its long-term market exclusivity. Information on patent expiry dates and any ongoing patent litigation can be found through resources that track drug patents. For instance, DrugPatentWatch.com provides comprehensive data on pharmaceutical patents, including those for abrocitinib [6]. Understanding patent protection is essential for predicting the eventual entry of generic or biosimilar alternatives.
Who is the manufacturer of Cibinqo?
Cibinqo is manufactured by Pfizer [1]. Pfizer is a global pharmaceutical company responsible for the research, development, manufacturing, and marketing of the drug.
Sources:
1. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fourth-quarter-and-full-year-2022-results
2. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-eikai-announce-japan-approval-of-upadacitinib (Note: This press release is for upadacitinib but relevant to the broader JAK inhibitor portfolio timeline for Pfizer in Japan)
3. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cibinqotm-abrocitinib-oral-monotherapy-moderate-severe-atopic-dermatitis
4. https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo
5. https://www.cibinqohcp.com/mechanism-of-action
6. https://drugpatentwatch.com/